ORCHPHARMA Orchid Pharma Q2 FY26 results (Jul–Sep 2025) and concall
Orchid Pharma reported a challenging Q2 FY26 with sales declining 13% YoY to ₹194 crores and global margins contracting to 32% from 43% QoQ, leading to an EBITDA of ₹6 crores. The company faced persistent volume and price pressure in the global antibiotics market, exacerbated by inventory revaluation. Despite headwinds, strategic initiatives like the acquisition of global rights for Enmetazobactam (Exblifep) and progress on the 7ACA and Cefiderocol projects are expected to build a stronger foundation for future growth.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue down 13.1%, net profit down 121.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 223 | 217 | 237 | 263 | 194 −13% |
| EBITDA | 30 | 26 | 28 | -6 | -1 −105% |
| Net profit | 27 | 21 | 22 | -6 | -6 −121% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
